astrazeneca glp 1 drug enters weight-loss market with oral GLP-1 Astrazeneca divulges new GLP-1R agonists

Ohtake et al

Zepbound/Wegovy vs Mounjaro/Ozempic Mounjaro and Ozempic are the diabetes versions of Zepbound and Wegovy respectively

With proper medical guidance and access to quality medications, GLP-1 treatment can be both safe and effective for managing diabetes and achieving sustainable weight loss

Research in animal models and population studies suggests GLP-1 receptor agonists may reduce dementia risk and improve cognitive function, but clinical trials are still ongoing

Methods 3.1

Experts say GLP-1 drugs in tablet form may encourage more people to take these medications to help treat type 2 diabetes and obesity